MRVI

Maravai LifeSciences Holdings, Inc. [MRVI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MRVI Stock Summary

Top MRVI Correlated Resources

MRVI


Top 10 Correlated ETFs

MRVI


Top 10 Correlated Stocks

MRVI


In the News

04:15 28 Mar 2024 MRVI

Maravai LifeSciences Announces March 2024 Investor Conference Schedule

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.

05:00 28 Mar 2024 MRVI

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.

08:00 28 Mar 2024 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

08:15 28 Mar 2024 MRVI

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

03:54 28 Mar 2024 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

08:15 28 Mar 2024 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

04:36 28 Mar 2024 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

04:05 28 Mar 2024 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

07:52 28 Mar 2024 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

07:02 28 Mar 2024 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

MRVI Financial details

Company Rating
Neutral
Market Cap
1.16B
Income
-120.31M
Revenue
288.95M
Book val./share
3.15
Cash/share
4.35
Dividend
-
Dividend %
-
Employees
650
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
12.02
Forward P/E
858
PEG
-0.82
P/S
3.99
P/B
1.69
P/C
1.97
P/FCF
10.28
Quick Ratio
16.7
Current Ratio
8.96
Debt / Equity
1.28
LT Debt / Equity
0.66
-
-
EPS (TTM)
-0.91
EPS next Y
0.01
EPS next Q
-
EPS this Y
-146.88%
EPS next Y
-101.41%
EPS next 5Y
-140.65%
EPS last 5Y
72.75%
Revenue last 5Y
15.08%
Revenue Q/Q
10.88%
EPS Q/Q
1500%
-
-
-
-
SMA20
20.82%
SMA50
25.8%
SMA100
24.66%
Inst Own
74.65%
Inst Trans
0.8%
ROA
3%
ROE
14%
ROC
0.04%
Gross Margin
60%
Oper. Margin
19%
Profit Margin
17%
Payout
-
Shs Outstand
132.31M
Shs Float
106.79M
-
-
-
-
Target Price
23.5
52W Range
4.52-16.62
52W High
-46.38%
52W Low
+114.5%
RSI
63.96
Rel Volume
0.65
Avg Volume
2.66M
Volume
1.73M
Perf Week
7.79%
Perf Month
66.93%
Perf Quarter
-11.27%
Perf Half Y
-7.74%
-
-
-
-
Beta
-0.025
-
-
Volatility
0.24%, 1.12%
Prev Close
2.88%
Price
8.58
Change
-1.49%

MRVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.619.833.13.462.19
Net income per share
-0.062.661.821.92-0.9
Operating cash flow per share
0.275.261.432.10.96
Free cash flow per share
0.084.391.372.030.46
Cash per share
0.288.172.142.484.36
Book value per share
1.593.061.222.143.16
Tangible book value per share
-3.12-8.551.071.591.84
Share holders equity per share
1.593.061.222.143.16
Interest debt per share
4.7221.52.192.374.38
Market cap
2.66B810.87M10.8B3.65B864.07M
Enterprise value
3.02B1.17B10.78B3.61B900.07M
P/E ratio
-510.610.5523.027.45-7.26
Price to sales ratio
18.552.8513.524.142.99
POCF ratio
110.125.3329.316.826.85
PFCF ratio
381.176.430.547.0414.24
P/B Ratio
18.789.1634.246.72.07
PTB ratio
18.789.1634.246.72.07
EV to sales
21.114.113.494.083.12
Enterprise value over EBITDA
62.2812.4719.846.3520.19
EV to operating cash flow
125.287.6629.266.737.13
EV to free cash flow
433.639.1930.496.9514.84
Earnings yield
00.090.040.13-0.14
Free cash flow yield
00.160.030.140.07
Debt to equity
2.766.671.691.071.28
Debt to assets
0.680.460.280.260.36
Net debt to EBITDA
7.533.8-0.03-0.080.81
Current ratio
2.052.547.897.78
Interest coverage
0.82.218.3328.13-0.09
Income quality
-4.641.930.791.09-1.06
Dividend Yield
00.75000
Payout ratio
07.92000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.030.030.020.020.06
Intangibles to total assets
0.730.320.140.220.37
Capex to operating cash flow
-0.71-0.17-0.04-0.03-0.52
Capex to revenue
-0.12-0.09-0.02-0.02-0.23
Capex to depreciation
-0.71-0.98-0.6-0.45-1.34
Stock based compensation to revenue
0.010.090.010.020.12
Graham number
1.4513.547.089.618.01
ROIC
0.040.090.570.430
Return on tangible assets
-0.030.090.280.28-0.13
Graham Net
-4.36-28.53-2.75-2.4-0.42
Working capital
30.99M200.82M646.26M737.76M612.44M
Tangible asset value
-277.5M-247.19M275.02M404.91M242.87M
Net current asset value
-372.62M-784.35M-632.88M-529.17M2.35M
Invested capital
2.766.671.691.071.28
Average receivables
17.01M34.52M84.27M132.16M101.27M
Average payables
5.54M7.82M8.16M7.07M8.36M
Average inventory
14.26M23.75M42.43M47.35M47.27M
Days sales outstanding
45.9865.5553.6760.6970.39
Days payables outstanding
40.8337.4421.1712.9425.88
Days of inventory on hand
77.54152.61133.8893.22123.96
Receivables turnover
7.945.576.86.015.19
Payables turnover
8.949.7517.2428.214.11
Inventory turnover
4.712.392.733.922.94
ROE
-0.040.871.490.9-0.29
Capex per share
-0.19-0.88-0.06-0.07-0.5

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.560.60.530.520.56
Net income per share
0.66-0.01-0.05-0.05-0.8
Operating cash flow per share
0.750.650.150.110.06
Free cash flow per share
0.710.59-0.04-0.01-0.07
Cash per share
4.84.774.434.484.35
Book value per share
4.143.963.984.023.15
Tangible book value per share
3.082.522.572.621.84
Share holders equity per share
4.143.963.984.023.15
Interest debt per share
4.524.774.774.214.14
Market cap
1.88B1.85B1.63B1.29B865.52M
Enterprise value
1.84B1.83B1.66B1.33B901.52M
P/E ratio
5.39-342.3-62.15-50-2.04
Price to sales ratio
9.223.3623.619.3311.67
POCF ratio
18.9621.6984.7291.23111.11
PFCF ratio
20.2323.91-277.25-778.09-96.07
P/B Ratio
3.453.543.122.492.08
PTB ratio
3.453.543.122.492.08
EV to sales
8.9723.224.1319.8512.16
Enterprise value over EBITDA
16.33209.66-189.88-239.8868.33
EV to operating cash flow
18.4921.5586.6593.71115.73
EV to free cash flow
19.7223.75-283.58-799.2-100.07
Earnings yield
0.0500-0.01-0.12
Free cash flow yield
0.050.0400-0.01
Debt to equity
1.071.181.191.031.28
Debt to assets
0.260.270.270.230.36
Net debt to EBITDA
-0.42-1.37-4.23-6.342.73
Current ratio
7.76.139.338.968
Interest coverage
10.73-0.18-1.65-1.320.01
Income quality
1.14-63.11-1.61-2.19-0.07
Dividend Yield
00000
Payout ratio
0-0.25000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.020.050.060.070.06
Intangibles to total assets
0.220.250.250.240.37
Capex to operating cash flow
-0.06-0.09-1.31-1.12-2.16
Capex to revenue
-0.03-0.1-0.36-0.24-0.23
Capex to depreciation
-0.62-0.72-2.12-1.21-1.29
Stock based compensation to revenue
0.030.080.130.150.13
Graham number
7.870.952.122.137.54
ROIC
0.080-0.01-0.010
Return on tangible assets
0.05000-0.11
Graham Net
-4.66-5.44-5.55-5.68-0.42
Working capital
737.76M640.62M624.39M622.61M612.44M
Tangible asset value
404.91M332.49M336.45M338.4M242.87M
Net current asset value
-529.17M-649.24M-667.49M-674.41M2.35M
Invested capital
1.071.181.191.031.28
Average receivables
139.52M101.85M53.05M49.21M52.46M
Average payables
7.73M5.39M5.72M8.04M10.08M
Average inventory
52.79M48.99M51.11M48.27M50.27M
Days sales outstanding
64.5564.7964.2866.2367.64
Days payables outstanding
10.1312.7913.8523.1227.04
Days of inventory on hand
72.93146.5198.59120.56129.54
Receivables turnover
1.391.391.41.361.33
Payables turnover
8.897.046.53.893.33
Inventory turnover
1.230.610.910.750.69
ROE
0.160-0.01-0.01-0.25
Capex per share
-0.05-0.06-0.19-0.12-0.13

MRVI Frequently Asked Questions

What is Maravai LifeSciences Holdings, Inc. stock symbol ?

Maravai LifeSciences Holdings, Inc. is a US stock , located in San diego of Ca and trading under the symbol MRVI

Is Maravai LifeSciences Holdings, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $22 and the highest is $25

What is MRVI stock prediction ?

What is Maravai LifeSciences Holdings, Inc. stock quote today ?

Maravai LifeSciences Holdings, Inc. stock price is $8.58 today.

Is Maravai LifeSciences Holdings, Inc. stock public?

Yes, Maravai LifeSciences Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap